Kisunla
(donanemab) IV
- For early Alzheimer’s disease: mild cognitive impairment or mild dementia
- Amyloid must be confirmed first, by an amyloid blood biomarker test, an amyloid PET scan, or a spinal fluid (CSF) test
- Scheduled MRI scans watch for ARIA, a side effect that can cause brain swelling or small bleeds
- Treatment may be stopped once a PET scan shows amyloid has been reduced to minimal levels